Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
With the growing prevalence of various genetic and chronic diseases, cloning of genes is extensively used in the detection of such issues and in their treatment through methods like gene therapy. Hence, the rising cases of sickle cell anaemia and leukaemia, among others, are driving the cloning and mutagenesis market.
The increasing cloning of genes in the synthesis of antibiotics, hormones, and vitamins, among others, for the treatment of issues such as cystic fibrosis is propelling the market growth. The market growth can also be attributed to the rising use of cloning in supporting new discoveries for therapeutics, vaccine development, and various emerging synthetic biology applications. Furthermore, the increasing research activities to develop next-generation cloning for creating custom vectors for any application are likely to fuel the market growth.
The addition of cloning in various advanced systems by the leading companies is propelling the cloning and mutagenesis market. In May 2021, Codex DNA, Inc. (NASDAQ: DNAY) announced the addition of a longer fragment cloning to its BioXp™ system, which is a fully automated benchtop instrument facilitating various synthetic biology workflows. It would eliminate the requirement to manually synthesise error-corrected genes.
The addition of longer fragment cloning would also enable scientists to produce multivariant, error-corrected, de novo synthetic genes up to 7.2 kilobase pairs (kb) in length. The cloning of them into custom vectors could be done overnight and hands-free by using the company’s Gibson Assembly technology.
Moreover, the 7.2 kb length expands the use of the BioXp™ system to enable researchers to study proteins larger than human proteins. This would also boost the use of the system in various applications such as metabolic engineering, antibody engineering, small genome construction, and targeted gene variant analysis, among others.
The major players in the global cloning and mutagenesis market are Thermo Fisher Scientific Inc., Takara Bio Inc., Codex DNA, Inc., Agilent Technologies, Inc., and TransGen Biotech Co., Ltd., among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.